Representative Jefferson Shreve (R-Indiana) recently sold shares of CVS Health Corporation NYSE: CVS. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in CVS Health stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
- Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
- Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
- Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
- Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
- Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
- Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
- Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.
CVS Health Price Performance
Shares of NYSE:CVS traded up $1.92 during trading on Friday, reaching $60.67. The company had a trading volume of 10,876,795 shares, compared to its average volume of 6,689,161. The company has a fifty day moving average of $64.61 and a two-hundred day moving average of $63.66. The stock has a market capitalization of $76.75 billion, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. CVS Health Corporation has a 12 month low of $43.56 and a 12 month high of $72.51. The company has a current ratio of 0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The firm had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. During the same quarter in the prior year, the firm earned $1.31 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. Equities research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.
CVS Health Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.38%. The ex-dividend date is Tuesday, July 22nd. CVS Health's payout ratio is 63.48%.
Wall Street Analyst Weigh In
Several equities analysts recently commented on CVS shares. UBS Group reduced their target price on shares of CVS Health from $71.00 to $67.00 and set a "neutral" rating on the stock in a report on Tuesday, July 22nd. Robert W. Baird increased their target price on shares of CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Mizuho increased their target price on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Barclays set a $79.00 price target on shares of CVS Health and gave the company an "overweight" rating in a research report on Monday, June 2nd. Finally, Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $74.82.
View Our Latest Report on CVS
Insider Transactions at CVS Health
In other CVS Health news, Director Guy P. Sansone purchased 1,570 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the transaction, the director directly owned 12,007 shares in the company, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.22% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On CVS Health
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in CVS Health by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock valued at $8,017,223,000 after acquiring an additional 969,027 shares during the period. Dodge & Cox lifted its position in CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator's stock valued at $4,976,856,000 after acquiring an additional 3,353,223 shares during the period. Capital World Investors lifted its position in CVS Health by 26.6% during the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after acquiring an additional 12,819,148 shares during the period. Geode Capital Management LLC lifted its position in CVS Health by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock valued at $1,211,582,000 after acquiring an additional 689,867 shares during the period. Finally, Capital International Investors lifted its position in CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after acquiring an additional 1,212,126 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
MarketBeat All Access